Meeting
2023 ASCO Annual Meeting
Clinical development of the bispecific PSMAxCD3 antibody CC-1.
Authors
Christopher Hackenbruch
University Hospital Tübingen, German Cancer Consortium (DKTK), Department of Internal Medicine, Clinical Collaboration Unit Translational Immunology, Tübingen, Germany
Christopher Hackenbruch , Jonas S. Heitmann , Juliane S. Walz , Birgit Federmann , Martin Pflügler , Richard F. Schlenk , Sebastian Ochsenreither , Boris A. Hadaschik , Christopher Darr , Viktor Grünwald , Gundram Jung , Helmut R. Salih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT04104607, NCT04496674, NCT05646550
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2534)
DOI
10.1200/JCO.2023.41.16_suppl.2534
Abstract #
2534
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer.
First Author: Christopher Hackenbruch
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Susan F. Slovin
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2022 ASCO Annual Meeting
An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.
First Author: Kaiwen Li